EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade

Olta Ibruli, France Rose, Filippo Beleggia, Anna Schmitt, Maria Cartolano, Lucia Torres Fernandez, Julia Saggau, Debora Bonasera, Martha Kiljan, Gokcen Gozum, Luca Lichius, Jiali Cai and 13 more

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05942-9 ↗

At a glance

Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Olta Ibruli and 24 co-authors. Institution: Department of Translational Genomics, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. Major MEDLINE topics: Immune Checkpoint Inhibitors, Small Cell Lung Carcinoma, Lung Neoplasms, DNA Mismatch Repair. Cited 6 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft (SFB1399), Deutsche Krebshilfe, Mildred Scheel Nachwuchszentrum.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Purpose

Small cell lung cancer (SCLC) has an extremely poor prognosis. Despite high initial response rates to chemotherapy and modest survival improvements with the addition of immune checkpoint inhibitors (ICI), almost all patients experience relapse and fatal outcomes. Recent genomic insights uncovered extensive molecular heterogeneity in addition to the almost uniform loss of RB1 and TRP53 . Additionally, defective DNA mismatch repair (MMR) has recently been described in some SCLC cases. Here, we generated a novel SCLC mouse model capturing MMR deficiency and assessed immunotherapy responses.

Methods

We developed an MMR-deficient genetically engineered mouse model (GEMM) of SCLC by introducing a conditional Msh2 gene, crucial for maintaining MMR integrity, into the standard Rb1 fl/fl ; Trp53 fl/fl (RP) model. Genomic characteristics and preclinical therapy responses were evaluated by focusing on overall survival and whole exome sequencing (WES) analyses.

Results

MMR-defective SCLC tumors ( Rb1 fl/fl ; Trp53 fl/fl ; Msh2 fl/fl (RPM)) developed later than tumors in MMR-proficient mice. However, the time from tumor manifestation to death of the affected animals was substantially shortened (median survival 55 days in RP vs. 46.5 days in RPM), indicating increased aggressiveness of MMR-defective tumors. RPM tumors exhibited MMR deficiency, high tumor mutational burden (TMB), and an elevated load of candidate neoantigens, compared to RP lesions ( p = 0.0106), suggesting increased immunogenicity. Importantly, the overall survival of RPM animals was significantly improved when exposed to ICI.

Conclusion

We propose a novel RPM mouse model as a suitable system to mimic MMR-defective SCLC and tumors with high TMB. We provide in vivo evidence that Msh2 deficiency enhances ICI sensitivity. These findings could contribute to stratifying SCLC patients to immunotherapy, thereby improving treatment outcomes.

Subjects

MeSH terms (MEDLINE)

Immune Checkpoint InhibitorsSmall Cell Lung CarcinomaLung NeoplasmsDNA Mismatch RepairDisease Models, AnimalMutS Homolog 2 ProteinAnimalsMiceHumansTumor Suppressor Protein p53

Author keywords

Genetically engineered mouse modelImmune checkpoint inhibitorMismatch repair deficiencySmall cell lung cancerTumor mutational burden

Substances

Immune Checkpoint InhibitorsMutS Homolog 2 ProteinMsh2 protein, mouseTumor Suppressor Protein p53

Authors and institutions

  • Department of Translational Genomics, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute for Biomedical Informatics, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.

Funding

  • Deutsche Forschungsgemeinschaft (SFB1399)
  • Deutsche Krebshilfe
  • Mildred Scheel Nachwuchszentrum
  • Center for Molecular Medicine Cologne, University of Cologne
  • Alexander von Humboldt-Stiftung
  • Medical Research Council
  • Cancer Research UK Programme
  • Center for Biochemistry, Univeristy of Cologne

Cite

APA

Ibruli, O., Rose, F., Beleggia, F., Schmitt, A., Cartolano, M., Fernandez, L. T., Saggau, J., Bonasera, D., Kiljan, M., Gozum, G., Lichius, L., Cai, J., Niu, L. N., Caiaffa, M. I., Herter, J. M., Walczak, H., Liccardi, G., Grüll, H., Büttner, R., …, & Herter-Sprie, G. S. (2024). A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05942-9

Vancouver

Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Fernandez LT, et al. A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05942-9

BibTeX
@article{Ibruli2024,
  author = {Ibruli, Olta and Rose, France and Beleggia, Filippo and Schmitt, Anna and Cartolano, Maria and Fernandez, Lucia Torres and Saggau, Julia and Bonasera, Debora and Kiljan, Martha and Gozum, Gokcen and Lichius, Luca and Cai, Jiali and Niu, Li-Na and Caiaffa, Manoela Iannicelli and Herter, Jan M and Walczak, Henning and Liccardi, Gianmaria and Grüll, Holger and Büttner, Reinhard and Bosco, Graziella and George, Julie and Thomas, Roman K and Bozek, Kasia and Reinhardt, Hans Christian and Herter-Sprie, Grit S},
  title = {A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05942-9}
}
Start for free →